Payment overview · 2025
General Payments
$308.87
15 reported records · 8 companies
Healthcare provider profile · identity verified
Imad Haddad, MD
Allopathic & Osteopathic Physicians|General Practice · SPRINGFIELD, KY · NPI 1508880063
Verified facts
What the public records show
CMS Open Payments records show Imad Haddad, MD received $308.87 in general payments during 2025 across 15 reported records.
Vanda Pharmaceuticals Inc. accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $112.21 | 36.3% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.07 | 17.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.63 | 14.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $25.18 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.07 | 6.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.97 | 6.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.47 | 6.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.27 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $308.87 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $112.21 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.07 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.63 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 239 | 77 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 205 | 77 |
| Gabapentin | Gabapentin | 198 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 53 |
| Losartan Potassium | Losartan Potassium | 167 | 45 |
| Meloxicam | Meloxicam | 158 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 39 |
| Metformin Hcl Er | Metformin Hcl | 140 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 65 |
| Tramadol Hcl | Tramadol Hcl | 135 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 133 | 35 |
| Furosemide | Furosemide | 132 | 44 |
| Omeprazole | Omeprazole | 127 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 27 |
| Lisinopril | Lisinopril | 110 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 35 |
| Montelukast Sodium | Montelukast Sodium | 94 | 27 |
| Valsartan | Valsartan | 89 | 24 |
| Carvedilol | Carvedilol | 84 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 22 |
| Methocarbamol | Methocarbamol | 78 | 31 |
| Sertraline Hcl | Sertraline Hcl | 77 | 22 |
| Spironolactone | Spironolactone | 75 | 20 |
| Buspirone Hcl | Buspirone Hcl | 74 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 23 |
| Potassium Chloride | Potassium Chloride | 66 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 62 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 33 |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | 15 |
| Cefdinir | Cefdinir | 57 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 17 |
| Trazodone Hcl | Trazodone Hcl | 52 | 19 |
| Glipizide Er | Glipizide | 49 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 16 |
| Methylprednisolone | Methylprednisolone | 48 | 35 |
| Eliquis | Apixaban | 47 | 11 |
| Famotidine | Famotidine | 46 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Alprazolam | Alprazolam | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 17 |
| Allopurinol | Allopurinol | 36 | 11 |
| Januvia | Sitagliptin Phosphate | 36 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 24 |
| Clonidine Hcl | Clonidine Hcl | 34 | 12 |
| Topiramate | Topiramate | 34 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 22 |
| Metformin Hcl | Metformin Hcl | 29 | suppressed |
| Prednisone | Prednisone | 29 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 12 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 13 |
| Lorazepam | Lorazepam | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | 14 |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 22 |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 15 |
| Diclofenac Sodium Er | Diclofenac Sodium | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | 11 |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Methimazole | Methimazole | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $308.87 · 15 records | Vanda Pharmaceuticals Inc. | CAPLYTA, Cologuard Collection Kit, FANAPT, MOUNJARO, OTEZLA, Ohtuvayre, REPATHA, TRELEGY ELLIPTA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error